Withdrawal of Inhaled Corticosteroids and Exacerbations of COPD (WISDOM)
Source: View publication →
In patients with severe to very severe COPD receiving triple therapy, stepwise withdrawal of inhaled corticosteroids did not significantly increase the risk of moderate or severe exacerbations compared with continuing triple therapy over 52 weeks.
Key Findings
Study Design
Study Limitations
Clinical Significance
The WISDOM trial challenged the dogma that all patients with severe COPD and a history of exacerbations require continuous inhaled corticosteroid therapy, suggesting that ICS can be withdrawn in many patients without increasing moderate-to-severe exacerbation risk, provided they are maintained on dual bronchodilator therapy. However, the potential for a small decline in lung function and increased risk in eosinophilic patients necessitates a personalized, risk-based approach to ICS withdrawal.
Historical Context
Prior to WISDOM, clinical guidelines heavily favored the inclusion of inhaled corticosteroids in the maintenance therapy of patients with severe COPD and frequent exacerbations. This trial was a landmark study that initiated a paradigm shift toward questioning the overuse of ICS, which carries risks of adverse effects like pneumonia, and promoting dual bronchodilation as the backbone of COPD management.
Guided Discussion
High-yield insights from every perspective
Why is the role of inhaled corticosteroids (ICS) in the management of COPD considered fundamentally different from their role in asthma, particularly regarding the underlying cellular inflammatory profile?
Key Response
In asthma, the inflammation is typically eosinophilic and Th2-driven, which is highly responsive to steroids. In contrast, COPD inflammation is primarily neutrophilic and Th1-driven, which is relatively steroid-resistant. The WISDOM trial tests the hypothesis that because this underlying inflammation is less responsive, the ICS component of triple therapy may be redundant in certain COPD phenotypes.
In a patient with severe COPD currently stable on triple therapy (ICS/LABA/LAMA), what specific clinical factors from the WISDOM trial results should guide your decision to attempt a stepwise withdrawal of the ICS component?
Key Response
The WISDOM trial suggests that in patients with severe to very severe airflow limitation who are stable on long-acting dual bronchodilators (LABA/LAMA), ICS can be withdrawn without increasing the risk of moderate-to-severe exacerbations. However, clinicians should monitor for a potential slight decline in FEV1 and consider the patient's individual history of exacerbations and pneumonia risk before proceeding.
Post-hoc analyses of the WISDOM trial identified a specific biomarker threshold that predicted a higher risk of exacerbations upon ICS withdrawal; how does this finding reconcile the trial's primary non-inferiority result with the concept of 'ICS-responsive' COPD phenotypes?
Key Response
While the primary trial met non-inferiority for the overall population, subsequent analysis showed that patients with blood eosinophil counts ≥300 cells/µL experienced a significant increase in exacerbation frequency after ICS withdrawal. This indicates that the 'non-inferiority' observed was an average effect, and that precision medicine using eosinophils is necessary to identify the subset of COPD patients who derive true benefit from ICS.
Given that the WISDOM trial demonstrated a statistically significant (though small) decrease in FEV1 following ICS withdrawal, how do you balance this physiological decline against the reduction in long-term steroid-related adverse effects when teaching de-escalation strategies?
Key Response
The withdrawal group saw an FEV1 decline of approximately 38-43 mL. While statistically significant, this is often considered below the threshold of clinical importance for an individual patient. Attendings should teach that for many patients, avoiding the increased risk of pneumonia, oral candidiasis, and bone density loss associated with long-term ICS use outweighs the minor physiological loss in lung function.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The WISDOM trial utilized a 'stepwise' withdrawal of ICS over 12 weeks rather than abrupt cessation; what are the methodological implications of this tapering design on the trial's ability to detect a rebound inflammatory effect or acute treatment failure?
Key Response
Stepwise withdrawal minimizes the risk of an acute 'rebound' effect by allowing the airway's homeostatic mechanisms to adjust. While this increases the safety and clinical relevance of the trial (mimicking real-world practice), it potentially masks more immediate ICS-dependency signals that an abrupt cessation design might have revealed, thus potentially biasing the results toward non-inferiority.
A critical reviewer might argue that the WISDOM trial's non-inferiority margin of 1.20 for the hazard ratio was too permissive; how does the choice of this margin influence the interpretation of 'safety' in the context of a drug withdrawal study?
Key Response
In non-inferiority trials, the margin represents the maximum acceptable loss of efficacy. A margin of 1.20 means the study could conclude 'non-inferiority' even if the withdrawal group had a 20% higher risk of exacerbations. As an editor, one must weigh whether a 20% increased risk is clinically acceptable for a 'stable' patient, especially when the intervention is the removal of a standard-of-care medication.
How do the results of the WISDOM trial, in conjunction with the SUNSET study, inform the current GOLD (Global Initiative for Chronic Obstructive Lung Disease) recommendations regarding 'de-escalation' of therapy?
Key Response
The WISDOM trial provides the evidence base for GOLD's current stance that ICS withdrawal is feasible in stable patients on dual bronchodilation, provided they do not have high blood eosinophils (typically <300 cells/µL) or a history of frequent exacerbations. It shifted the guidelines from a 'escalation-only' mindset to a dynamic approach where therapy is tailored to the patient's current risk-benefit profile, specifically recommending caution in withdrawal for those with an eosinophilic phenotype.
Clinical Landscape
Noteworthy Related Trials
TORCH Trial
Tested
Salmeterol/Fluticasone propionate combination
Population
Patients with moderate-to-severe COPD
Comparator
Placebo, Salmeterol alone, and Fluticasone propionate alone
Endpoint
All-cause mortality
OPTIMAL Trial
Tested
Withdrawal of inhaled corticosteroids
Population
Patients with stable COPD receiving triple therapy
Comparator
Continued triple therapy
Endpoint
Time to first moderate or severe exacerbation
FLAME Trial
Tested
Indacaterol/Glycopyrronium dual bronchodilation
Population
Patients with COPD and a history of exacerbations
Comparator
Salmeterol/Fluticasone
Endpoint
Annual rate of all COPD exacerbations
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis